Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | USP19 | O94966 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640352 | 0.81 | LMNA (0.55) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1640573 | 0.78 | BRD4 (0.65) | HPGDALDH1A1MAPTGAA | |
| SCHEMBL1641959 | 0.78 | KDM4E (0.48) | HSP90AA1KMT2AHPGDALDH1A1HSP90AB1 | |
| SCHEMBL1641929 | 0.76 | CRHBP (0.61) | ALDH1A1 | |
| SCHEMBL1641827 | 0.75 | BRD4 (0.57) | KMT2AMEN1MAPT | |
| SCHEMBL20677835 | 0.75 | HSP90AA1 (1.00) | HSP90AA1KMT2AHPGDMEN1ALDH1A1 | |
| SCHEMBL1642053 | 0.74 | MAPT (0.59) | KMT2AHPGDMEN1ALDH1A1MAPT | |
| SCHEMBL1640326 | 0.74 | HSP90AA1 (0.58) | HSP90AA1KMT2AHPGDMEN1ALDH1A1 | |
| SCHEMBL1642389 | 0.74 | EGLN1 (0.48) | ALDH1A1GAA | |
| SCHEMBL1641629 | 0.72 | BRD4 (0.59) | KMT2AHPGDMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2306828-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxosmithkline LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | HSP90AA1 789/4885KMT2A 759/4885HPGD 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.